NOTCH3 as a modulator of vascular disease: a target in elastin deficiency and arterial pathologies

Authors

Kimberly Malka, Maine Medical Partners Vascular Surgery and.
Lucy Liaw, Maine Medical Center Research Institute, MaineHealth, Scarborough, Maine, USA.Follow

Document Type

Article

Publication Date

3-1-2022

Journal Title

The Journal of clinical investigation

Abstract

During blood vessel disease, vascular smooth muscle cell (VSMC) expansion and interaction with the matrix trigger changes in gene expression and phenotype. In this issue of the JCI, Dave et al. discover a signaling network that drives VSMC expansion and vascular obstruction caused by elastin insufficiency. Using a combination of gene-targeted mice, tissues and cells from patients with Williams-Beuren syndrome, and targeting of elastin in human VSMCs, the authors identified VSMC-derived NOTCH3 signaling as a critical mediator of aortic hypermuscularization and loss of vascular patency. NOTCH3-specific therapies or therapies that target downstream molecular pathways may provide opportunities to minimize VSMC growth and treat cardiovascular disease with minimal side effects.

Recommended Citation

Malka K, Liaw L. NOTCH3 as a modulator of vascular disease: a target in elastin deficiency and arterial pathologies. J Clin Invest. 2022;132(5):e157007. doi:10.1172/JCI157007